A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)

American Journal of Hematology

Volumn 93, Issue 2, 2018, Pages 159-168

  Tanabe, Paula ^a   Silva, Susan ^a   Bosworth, Hayden B ^b,c   Crawford, Regina ^a   Paice, Judith A ^d   Richardson, Lynne D ^e   Miller, Christopher N ^f   Glassberg, Jeffrey ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b and School of Nursing ^*  (United States)

^c DUKE UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

emergency; pain; sickle cell disease; vaso occlusive crisis

Indexed keywords

HYDROMORPHONE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BLACK PERSON; BLOOD PRESSURE; BREATHING RATE; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; EMERGENCY WARD; FEMALE; HEART RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; OXYGEN SATURATION; PAIN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEDATION; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SIDE EFFECT; VASOOCCLUSIVE CRISIS; VISUAL ANALOG SCALE; CLINICAL PROTOCOL; COMPARATIVE STUDY; COMPLICATION; HOSPITALIZATION; PAIN MEASUREMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STANDARDS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; CLINICAL PROTOCOLS; FEMALE; HOSPITALIZATION; HUMANS; MALE; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85040179836     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24948     Document Type: Article

References (21)

1. Benjamin LJ, Dampier CD, Jacox A, et al. Guideline for the Management of Acute and Chronic Pain in Sickle-Cell Disease. Glenview, IL: American Pain Society; 1999.
2. Lanzkron S, Carroll CP, Haywood C. Jr., The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010;85(10):797–799.
3. Elixhauser A, Steiner CA. Readmissions to U.S. Hospitals by Diagnosis, 2010. Agency for Healthcare Research and Quality; August 2013. Statistical Brief #153.
4. Hirschon JM. In: Tanabe P, ed. Discussion of American College of Emergency Physicians Board Meeting discussion and approval of the Emergency Department Sickle Cell Care Coalition (EDSC3); 2016.
5. U.S. Department of Health and Human Services National Heart Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease, Expert Panel Report, 2014; 2014.
6. Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial. Am J Hematol. 2015;90(12):1099–1105.
7. Dampier CD, Smith WR, Wager CG, et al. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013;10(2):319–331.
8. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27(4):485–489.
9. McPherson M. Demystifying Opioid Conversion: A Guide for Effective Dosing. Bethesda, MD: American Society of Health-System Pharmacists; 2010.
10. American Pain Society. Principles of Analgesic Use. 7th Edition, Chicago, IL; 2016.
11. Brousseau DC, Scott JP, Badaki-Makun O, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015;126(14):1651–1657.
12. Gladwin M, Kato G, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011;305(9):893–902.
13. Morris C, Kuypers F, Lavrisha L, et al. A randomized, placebo-control trial of arginine therapy for the treatment ofchildren with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98(9):1375–1382.
14. Hardwick W, Givens T, Monroe K, King W, Lawley D. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15(3):179–182.
15. Uzun B, Kekec Z, Gurkan E. Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis. Am J Emerg Med. 2010;28(4):445–449.
16. Wright S, Norris R, Mitchell T. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann Emerg Med. 1992;21(8):925–928.
17. Benjamin L, Berkowitz L, Orringer E, et al. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood. 1986;67(5):1442–1447.
18. Gonzalez E, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain. Arch Intern Med. 1991;151(7):1373–1378.
19. Kavanagh PL, Sprinz PG, Wolfgang TL, et al. Improving the management of vaso-occlusive episodes in the pediatric emergency department. Pediatrics. 2015;136(4):e1016–e1025.
20. Krishnamurti L, Smith-Packard B, Gupta A, Campbell M, Gunawardena S, Saladino R. Impact of individualized pain plan on the emergency management of children with sickle cell disease. Pediatr Blood Cancer. 2014;61(10):1747–1753.
21. Tanabe P, Artz N, Mark Courtney D, et al. Adult emergency department patients with sickle cell pain crisis: a learning collaborative model to improve analgesic management. Acad Emerg Med. 2010;17(4):399–407.